Literature DB >> 15883838

Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec.

Vania Yotova1, Damian Labuda, Ewa Zietkiewicz, Dominik Gehl, Alan Lovell, Jean-François Lefebvre, Stéphane Bourgeois, Emilie Lemieux-Blanchard, Marcin Labuda, Hélène Vézina, Louis Houde, Marc Tremblay, Bruno Toupance, Evelyne Heyer, Thomas J Hudson, Claude Laberge.   

Abstract

Founder effects are largely responsible for changes in frequency profiles of genetic variants in local populations or isolates. They are often recognized by elevated incidence of certain hereditary disorders as observed in regions of Charlevoix and Saguenay-Lac-Saint-Jean (SLSJ) in Northeastern Quebec. Dominantly transmitted myotonic dystrophy (DM1) is highly prevalent in SLSJ where its carrier rate reaches 1/550, compared with 1/5,000 to 1/50,000 elsewhere. To shed light on the origin of DM1 in this region, we have screened 50 nuclear DM1 families from SLSJ and studied the genetic variation in a 2.05 Mb (2.9 cM) segment spanning the site of the expansion mutation. The markers analyzed included 22 biallelic SNPs and two microsatellites. Among 50 independent DM1 chromosomes, we distinguished ten DM1-associated haplotypes and grouped them into three haplotype families, A, B and C, based on the relevant extent of allele sharing between them. To test whether the data were consistent with a single entry of the mutation into SLSJ, we evaluated the age of the founder effect from the proportion of recombinant haplotypes. Taking the prevalent haplotype A1_21 (58%) as ancestral to all the disease-associated haplotypes in this study, the estimated age of the founder effect was 19 generations, long predating the colonization of Nouvelle-France. In contrast, considering A1_21 as ancestral to the haplotype family A only, yielded the estimated founder age of nine generations, consistent with the settlement of Charlevoix at the turn of 17th century and subsequent colonization of SLSJ. We conclude that it was the carrier of haplotype A (present day carrier rate of 1/730) that was a "driver" of the founder effect, while minor haplotypes B and C, with corresponding carrier rates of 1/3,000 and 1/10,000, respectively, contribute DM1 to the incidence level known in other populations. Other studies confirm that this might be a general scenario in which a major "driver" mutation/haplotype issued from a founder effect is found accompanied by distinct minor mutations/haplotypes occurring at background population frequencies.

Entities:  

Mesh:

Year:  2005        PMID: 15883838     DOI: 10.1007/s00439-005-1298-8

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  49 in total

1.  Demogenetic study of three populations within a region with strong founder effects.

Authors:  Eve-Marie Lavoie; Marc Tremblay; Louis Houde; Hélène Vézina
Journal:  Community Genet       Date:  2005

2.  Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy.

Authors:  B Brais; J P Bouchard; Y G Xie; D L Rochefort; N Chrétien; F M Tomé; R G Lafrenière; J M Rommens; E Uyama; O Nohira; S Blumen; A D Korczyn; P Heutink; J Mathieu; A Duranceau; F Codère; M Fardeau; G A Rouleau; A D Korcyn
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  Allele frequencies at microsatellite loci: the stepwise mutation model revisited.

Authors:  A M Valdes; M Slatkin; N B Freimer
Journal:  Genetics       Date:  1993-03       Impact factor: 4.562

4.  Linkage disequilibrium analysis in young populations: pseudo-vitamin D-deficiency rickets and the founder effect in French Canadians.

Authors:  M Labuda; D Labuda; M Korab-Laskowska; D E Cole; E Zietkiewicz; J Weissenbach; E Popowska; E Pronicka; A W Root; F H Glorieux
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

5.  Social transmission of reproductive behavior increases frequency of inherited disorders in a young-expanding population.

Authors:  F Austerlitz; E Heyer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

6.  Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families.

Authors:  J T Wang; C J Lin; S M Burridge; G K Fu; M Labuda; A A Portale; W L Miller
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

7.  Instability of a premutation allele in homozygous patients with myotonic dystrophy type 1.

Authors:  Claudia Abbruzzese; Sandro Costanzi Porrini; Bruno Mariani; Fiona K Gould; John P McAbney; Darren G Monckton; Tetsuo Ashizawa; Manlio Giacanelli
Journal:  Ann Neurol       Date:  2002-10       Impact factor: 10.422

8.  New founder haplotypes at the myotonic dystrophy locus in southern Africa.

Authors:  A Goldman; M Ramsay; T Jenkins
Journal:  Am J Hum Genet       Date:  1995-06       Impact factor: 11.025

9.  Convergent myotonic dystrophy (DM) haplotypes: potential inconsistencies in human disease gene localization.

Authors:  E J Whiting; C Tsilfidis; L Surh; A E MacKenzie; R G Korneluk
Journal:  Eur J Hum Genet       Date:  1995       Impact factor: 4.246

10.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

View more
  16 in total

1.  Mutations in C5ORF42 cause Joubert syndrome in the French Canadian population.

Authors:  Myriam Srour; Jeremy Schwartzentruber; Fadi F Hamdan; Luis H Ospina; Lysanne Patry; Damian Labuda; Christine Massicotte; Sylvia Dobrzeniecka; José-Mario Capo-Chichi; Simon Papillon-Cavanagh; Mark E Samuels; Kym M Boycott; Michael I Shevell; Rachel Laframboise; Valérie Désilets; Bruno Maranda; Guy A Rouleau; Jacek Majewski; Jacques L Michaud
Journal:  Am J Hum Genet       Date:  2012-03-15       Impact factor: 11.025

2.  Genomic and genealogical investigation of the French Canadian founder population structure.

Authors:  Marie-Hélène Roy-Gagnon; Claudia Moreau; Claude Bherer; Pascal St-Onge; Daniel Sinnett; Catherine Laprise; Hélène Vézina; Damian Labuda
Journal:  Hum Genet       Date:  2011-01-15       Impact factor: 4.132

Review 3.  Therapeutics development in myotonic dystrophy type 1.

Authors:  Erin Pennock Foff; Mani S Mahadevan
Journal:  Muscle Nerve       Date:  2011-05-23       Impact factor: 3.217

Review 4.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

5.  Myotonic dystrophy type 1.

Authors:  Cam-Tu Emilie Nguyen; Craig Campbell
Journal:  CMAJ       Date:  2016-06-06       Impact factor: 8.262

Review 6.  Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes.

Authors:  Kevin Yum; Eric T Wang; Auinash Kalsotra
Journal:  Curr Opin Genet Dev       Date:  2017-02-14       Impact factor: 5.578

7.  Congenital myotonic dystrophy in a national registry.

Authors:  Patrick Prendergast; Sandra Magalhaes; Craig Campbell
Journal:  Paediatr Child Health       Date:  2010-10       Impact factor: 2.253

8.  Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.

Authors:  Youjin Wang; Ruth M Pfeiffer; Rotana Alsaggaf; Wilhelmine Meeraus; Julia C Gage; Lesley A Anderson; Renée C Bremer; Nikoletta Nikolenko; Hanns Lochmuller; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-20       Impact factor: 7.396

9.  Oral motor movements and swallowing in patients with myotonic dystrophy type 1.

Authors:  Beatriz Ercolin; Fernanda Chiarion Sassi; Laura Davison Mangilli; Lucia Iracema Zanotto Mendonça; Suelly Cecilia Olivan Limongi; Claudia Regina Furquim de Andrade
Journal:  Dysphagia       Date:  2013-03-05       Impact factor: 3.438

10.  Relaxed Selection During a Recent Human Expansion.

Authors:  Stephan Peischl; Isabelle Dupanloup; Adrien Foucal; Michèle Jomphe; Vanessa Bruat; Jean-Christophe Grenier; Alexandre Gouy; K J Gilbert; Elias Gbeha; Lars Bosshard; Elodie Hip-Ki; Mawussé Agbessi; Alan Hodgkinson; Hélène Vézina; Philip Awadalla; Laurent Excoffier
Journal:  Genetics       Date:  2017-11-29       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.